Establishment and reliablity and validity test of the Symptom Assessment Scale for Patients Treated with Tumor Immune Checkpoint Inhibitors / 中国实用护理杂志

ABSTRACT

Objective:To develop a symptom assessment scale for tumor immune checkpoint inhibitor therapy, and test its reliability and validity.Methods:The test scale was formed through literature analysis, case investigation and Delphi expert correspondence. From June 2021 to February 2022, a questionnaire survey was conducted on 229 patients admitted in Tianjin Medical University Cancer Institute and Hospital treated with tumor immune checkpoint inhibitors to test its reliability and validity and formed a formal questionnaire.Results:The Symptom Assessment Scale for Patients Treated with Tumor Immune Checkpoint Inhibitors included 15 items, the Cronbach alpha coefficient of the scale was 0.792, each item was in the range of 0.753-0.785, and the test-retest reliability was 0.721. Exploratory factor analysis extracted 4 common factors, and the cumulative variance contribution rate was 53.79%; the content validity index was 0.811 while that of each item was 0.733-0.933; the correlation coefficient between the total score of the scale and the overall health status of the Cancer Quality of Life Core Scale was 0.504 ( P<0.01). Conclusions:The Symptom Assessment Scale for Patients Treated with Tumor Immune Checkpoint Inhibitors has good reliability and validity, and it is suitable for symptom assessment of related population.